Literature DB >> 512589

Integration of a virus membrane protein into the lipid bilayer of target cells as a prerequisite for immune cytolysis. Specific cytolysis after virosome-target cell fusion.

B Morein, D Barz, U Koszinowski, V Schirrmacher.   

Abstract

Structural requirements for membrane antigens on target cells to mediate immune cytolysis were studied in a model system with purified membrane proteins from Semliki Forest virus (SFV). These SFV spike proteins were isolated in the form of detergent- and lipid-free protein micelles (29S complexes) or, after reconstitution into lipid vesicles, in the form of virosomes. Both the 29S complexes and the virosomes were found to bind well to murine tumor cells (P815 or Eb). When these cells, however, were used as target cells in complement-dependent lysis or in antibody-dependent cell- mediated cytotoxicity assays in the presence of anti-SFV serum, they were not lysed, although they effectively bound the antibody and consumed complement. The same tumor cells infected with SFV served as positive controls in both assays. Different results were obtained when inactivated Sendai virus was added as a fusion reagent to the cells coated with either virosomes or 29S complexes. Under these conditions the virosome-coated cells became susceptible to SFV- specific lysis, whereas the 29S complex-coated cells remained resistant. Evidence that the susceptibility to lysis ofvirosome-coated cells was dependent on active fusion and, therefore, integration of the viral antigens into the lipid bilayer of the target cells was derived from control experiments with enzyme-treated Sendai virus preparations. The 29S complexes and the virosomes partially and selectively blocked the target cell lysis by anti-H-2 sera but not by anti-non-H-2 sera confirming our previous finding that major histocompatibility antigens serve as receptors for SFV. The general significance of these findings for mechanisms of immune cytolysis is dicussed.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 512589      PMCID: PMC2185719          DOI: 10.1084/jem.150.6.1383

Source DB:  PubMed          Journal:  J Exp Med        ISSN: 0022-1007            Impact factor:   14.307


  23 in total

1.  QUANTITATIVE TITRATIONS OF MOUSE H-2 ANTIBODIES USING CR-51-LABELLED TARGET CELLS.

Authors:  H WIGZELL
Journal:  Transplantation       Date:  1965-05       Impact factor: 4.939

2.  Protein measurement with the Folin phenol reagent.

Authors:  O H LOWRY; N J ROSEBROUGH; A L FARR; R J RANDALL
Journal:  J Biol Chem       Date:  1951-11       Impact factor: 5.157

3.  Correlation between the ability of tumor cells to resist humoral immune attack and their ability to synthesize lipid.

Authors:  S I Schlager; S H Ohanian; T Borsos
Journal:  J Immunol       Date:  1978-02       Impact factor: 5.422

4.  Fusion of Sendai virus with the target cell membrane is required for T cell cytotoxicity.

Authors:  M Gething; U Koszinowski; M Waterfield
Journal:  Nature       Date:  1978-08-17       Impact factor: 49.962

5.  The entry into host cells of Sindbis virus, vesicular stomatitis virus and Sendai virus.

Authors:  D P Fan; B M Sefton
Journal:  Cell       Date:  1978-11       Impact factor: 41.582

6.  Tumor metastases and cell-mediated immunity in a model system in DBA/2 mice. I. Tumor invasiveness in vitro and metastasis formation in vivo.

Authors:  V Schirrmacher; G Shantz; K Clauer; D Komitowski; H P Zimmermann; M L Lohmann-Matthes
Journal:  Int J Cancer       Date:  1979-02       Impact factor: 7.396

7.  T-cell cytotoxicity in the absence of viral protein synthesis in target cells.

Authors:  U Koszinowski; M J Gething; M Waterfield
Journal:  Nature       Date:  1977-05-12       Impact factor: 49.962

8.  Complement activation by measles virus cytotoxic antibodies: alternative pathway C activation by hemagglutination-inhibition antibodies but classical activation by hemolysin antibodies.

Authors:  A C Ehrnst
Journal:  J Immunol       Date:  1977-02       Impact factor: 5.422

9.  Liposomes as model membrane systems for immune attack. I. Transfer of antigenic determinants to lymphocyte membranes after interactions with hapten-bearing liposomes.

Authors:  K Ozato; H K Ziegler; C S Henney
Journal:  J Immunol       Date:  1978-10       Impact factor: 5.422

10.  Human (HLA-A and HLA-B) and murine (H-2K and H-2D) histocompatibility antigens are cell surface receptors for Semliki Forest virus.

Authors:  A Helenius; B Morein; E Fries; K Simons; P Robinson; V Schirrmacher; C Terhorst; J L Strominger
Journal:  Proc Natl Acad Sci U S A       Date:  1978-08       Impact factor: 11.205

View more
  6 in total

1.  Cytopathic effect of human immunodeficiency virus in T4 cells is linked to the last stage of virus infection.

Authors:  R Leonard; D Zagury; I Desportes; J Bernard; J F Zagury; R C Gallo
Journal:  Proc Natl Acad Sci U S A       Date:  1988-05       Impact factor: 11.205

2.  Stimulation of cytotoxic T cells by liposomes containing influenza virus or its components.

Authors:  C J Hackett; P M Taylor; B A Askonas
Journal:  Immunology       Date:  1983-06       Impact factor: 7.397

3.  A synthetic peptide induces long-term protection from lethal infection with herpes simplex virus 2.

Authors:  E Watari; B Dietzschold; G Szokan; E Heber-Katz
Journal:  J Exp Med       Date:  1987-02-01       Impact factor: 14.307

4.  Interactions of Semliki Forest virus spike glycoprotein rosettes and vesicles with cultured cells.

Authors:  M Marsh; E Bolzau; J White; A Helenius
Journal:  J Cell Biol       Date:  1983-02       Impact factor: 10.539

5.  Influenza virus subtype-specific cytotoxic T lymphocytes lyse target cells coated with a protein produced in E. coli.

Authors:  A Yamada; J F Young; F A Ennis
Journal:  J Exp Med       Date:  1985-11-01       Impact factor: 14.307

6.  Recognition of viral glycoproteins by influenza A-specific cross-reactive cytolytic T lymphocytes.

Authors:  U H Koszinowski; H Allen; M J Gething; M D Waterfield; H D Klenk
Journal:  J Exp Med       Date:  1980-04-01       Impact factor: 14.307

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.